J. Fischer – Successful Drug Discovery (2 Volume set, 2015)

Автор: J. Fischer
Название книги: Successful Drug Discovery (2 Volume set)
Формат: PDF
Жанр: Медицина
Страницы: 551
Качество: Изначально компьютерное, E-book

The first volume of the book series “Successful Drug Discovery” is focusing on new drug discoveries during the last decade, from established drugs to recently introduced drugs of all kinds: small–molecule–, peptide–, and protein–based drugs.
The role of serendipity is analyzed in some very successful drugs where the research targets of the lead molecule and the drug are different. Phenotypic and target–based drug discovery approaches are discussed from the viewpoint of pioneer drugs and analogues.
This volume gives an excellent overview of insulin analogues including a discussion of the properties of rapid–acting and long–acting formulations of this important hormone.
The major part of the book is devoted to case histories of new drug discoveries described by their key inventors. Eight case histories range across many therapeutic fields.
The goal of this book series is to help the participants of the drug research community with a reference book series and to support teaching in medicinal chemistry with case histories and review articles of new drugs.
Contents
General Aspects
Serendipitous Target-Based Drug Discoveries
Drug Discoveries and Molecular Mechanism of Action
Drug Class
Insulin Analogs – Improving the Therapy of Diabetes
Case Histories
The Discovery of Stendra ™ (Avanafil) for the Treatment of Erectile Dysfunction
Dapagliflozin, A Selective SGLT2 Inhibitor for Treatment of Diabetes
Elvitegravir, A New HIV-1 Integrase Inhibitor for Antiretroviral Therapy
Discovery of Linagliptin for the Treatment of Type 2 Diabetes Mellitus
The Discovery of Alimta (Pemetrexed)
Perampanel: A Novel, Noncompetitive AMPA Receptor Antagonist for the Treatment of Epilepsy
Discovery and Development of Telaprevir (Incivek ™) – A Protease Inhibitor to Treat Hepatitis C Infection
Antibody–Drug Conjugates: Design and Development of Trastuzumab

Retaining the successful approach found in the previous volume in this series, the inventors and primary developers of drugs that successfully made it to market tell the story of the drug's discovery and development and relate the often twisted route from the first candidate molecule to the final marketed drug.
11 selected case studies describe recently introduced drugs that have not been previously covered in textbooks or general references. These range across six different therapeutic fields and provide a representative cross-section of the current drug development efforts. Backed by copious data and chemical information, the insight and experience of the contributors makes this one of the most useful training manuals that a junior medicinal chemist can hope to find and has won the support and endorsement of IUPAC.
HDAC Inhibitor Anticancer DrugDiscovery
From DMSO to the Anticancer Compound SAHA, anUnusual Intellectual Pathway for Drug Design
Romidepsin and the Zinc-Binding Thiol Family of Natural Product HDAC Inhibitors
The Discovery and Development of Belinostat
Discovery and Development of Farydak (NVP-LBH589, Panobinostat) as an Anticancer Drug
Discovery and Development of HDAC Subtype Selective Inhibitor Chidamide: Potential Immunomodulatory Activity Against Cancers
Steroidal CYP17 Inhibitor Anticancer Drug Discovery
AbirateroneAcetate(Zytiga):AnInhibitorofCYP17asaTherapeutic for Castration-Resistant Prostate Cancer
[bAnti-Infective Drug Discoveries[/b]
Discovery of Delamanid for the Treatment of Multidrug-Resistant Pulmonary Tuberculosis
Sofosbuvir: The Discovery of a Curative Therapy for the Treatment of Hepatitis CVirus
Central Nervous System (CNS) Drug Discovery
TheDiscoveryoftheAntidepressantVortioxetineandtheResearch that Uncovered Its Potential to Treat the Cognitive Dysfunction Associated with Depression
Antiulcer Drug Discovery
Discovery of Vonoprazan Fumarate (TAK-438) as a Novel, Potent and Long-Lasting Potassium-Competitive Acid Blocker
Cross-Therapeutic Drug Discovery (Respiratory Diseases/Anticancer)
DiscoveryandDevelopmentofNintedanib:ANovelAntiangiogenic and Antifibrotic Agent